Evogene (EVGN) Accumulated Expenses (2016 - 2025)
Evogene (EVGN) posted Accumulated Expenses of $861000.0 for Q4 2025, down 18.7% sequentially from $1.1 million in Q3 2025, and down 53.93% YoY from $1.9 million in Q4 2024.
Evogene (EVGN) Accumulated Expenses (2016 - 2025) Analysis & Trends
Evogene has reported Accumulated Expenses for 10 years, with the latest figure at $861000.0 in Q4 2025.
- Quarterly Accumulated Expenses fell 53.93% year-over-year to $861000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $861000.0 (down 53.93% YoY) and the FY2025 annual result came in at $861000.0, down 53.93% from the prior year.
- Accumulated Expenses slipped to $861000.0 in Q4 2025 per EVGN's latest filing, from $1.1 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $2.7 million in Q4 2021 and troughed at $861000.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $2.3 million in 2021 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2025: Accumulated Expenses surged 66.46% in 2021, then sank 53.93% in 2025.
- Over 5 years, Accumulated Expenses stood at $2.7 million in 2021, then retreated by 25.36% to $2.0 million in 2022, then climbed by 27.68% to $2.5 million in 2023, then dropped by 26.33% to $1.9 million in 2024, then tumbled by 53.93% to $861000.0 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $861000.0, $1.1 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 861,000.00 |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Sep 30, 2023 | 2.06 Mn |
| Jun 30, 2023 | 2.16 Mn |
| Mar 31, 2023 | 2.04 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | 2.32 Mn |
| Jun 30, 2022 | 2.38 Mn |
| Mar 31, 2022 | 2.66 Mn |
| Dec 31, 2021 | 2.66 Mn |
| Sep 30, 2021 | 2.36 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Mar 31, 2021 | 2.40 Mn |